Page last updated: 2024-09-04

(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Parkinson Disease

(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with Parkinson Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ding, F; Li, M; Tian, Y; Xu, Q; Zhang, M; Zhu, M1

Other Studies

1 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Parkinson Disease

ArticleYear
Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson's disease.
    Biochemical and biophysical research communications, 2020, 01-22, Volume: 521, Issue:4

    Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Hyperalgesia; Male; Mice, Inbred C57BL; Oxidopamine; Pain Threshold; Parkinson Disease; Piperidines; Receptors, Serotonin, 5-HT3; Serotonin; Signal Transduction; Trigeminal Caudal Nucleus; TRPV Cation Channels

2020